Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4 publications
Prademagene Zamikeracel: First Approval.
Journal: Molecular diagnosis & therapy
Published: July 13, 2025
Prademagene zamikeracel (Zevaskyn) for recessive dystrophic epidermolysis bullosa.
Journal: The Medical letter on drugs and therapeutics
Published: July 12, 2025
Prademagene Zamikeracel.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: June 25, 2025
Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial.
Journal: Lancet (London, England)
Published: January 06, 2025
Showing 1-4 of 4
Last Updated: 10/31/2025